Health Care · Laboratory Analytical Instruments · NYSE · CIK 12208 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $326.72Day −0.16%Mkt cap $9.0BP/E (FY) 11.7×1Y +30.6%Off 52W high −4.8%Vol (1Y) 42.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,295 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesNEVER-OBSERVED · 75.0% growth |
| Short interest5.6% of sh out |
| Days to cover6.0d |
| 13F net flow (QoQ)+2.60% |
| Top-10 13F concentration49.4% |
| Next report (est.)2026-10-27 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)11.7× |
| Sales (TTM)$2.59B |
| Earnings (TTM)$168.8M |
| ROE10.8% |
| Net margin29.4% |
| ROIC0.5% |
| YTD+7.8% |
| 1Y+30.6% |
| 3Y−19.4% |
| 5Y−55.8% |
| 10Y+119.8% |
| Since incept. (ann.)+8.4% |
Total return through 2026-07-30 · series begins 2005-07-08. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)42.1% |
| Ann. volatility (3Y)38.0% |
| Sharpe (1Y)0.82 |
| Sharpe (3Y)−0.00 |
| Max drawdown (1Y)−28.9% |
| Max drawdown (3Y)−46.8% |
| Beta (3Y vs SPY)1.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| First Eagle Investment Management, LLC | 2.6M | $726M | — | +1.3% |
| BlackRock, Inc. | 1.7M | $468M | — | −0.1% |
| DIMENSIONAL FUND ADVISORS LP | 1.1M | $304M | — | +1.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 831,165 | $232M | — | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 829,186 | $231M | — | new |
| ARIEL INVESTMENTS, LLC | 785,961 | $219M | — | +2.8% |
| EARNEST PARTNERS LLC | 588,731 | $164M | — | −2.5% |
| STATE STREET CORP | 559,570 | $156M | — | −0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-30 | −$19.55 | −953.7% | $592.1M | +1.1% |
| 2025-12-31 | 2026-02-12 | — | — | $693.2M | +3.9% |
| 2025-09-30 | 2025-10-29 | −$12.70 | −154.4% | $653.0M | +0.5% |
| 2025-06-30 | 2025-07-31 | $11.67 | — | $651.6M | +2.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-27 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
Clinical Diagnostics 60% · Life Science 40%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Total debt / EBITDA5.65× |
| Sales growth 3Y−2.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
